Androgel Link To Heart Attacks?
AndroGel Maker AbbVie Denies Drug’s Heart Attack Connection
July 10, 2017
In an ongoing trial in Chicago, major drugmaker AbbVie asserted that no clinical studies exist that demonstrate a direct connection between its topical testosterone replacement drug AndroGel and an increased risk of heart attacks.
The central issue in the trial is whether AbbVie has falsely and potentially injuriously downplayed or covered up health risks that are alleged to be linked with AndroGel. Those alleged risks include heart attack and pulmonary embolism.
The drug manufacturer asserted that it was not obligated to inform doctors or patients of a heart attack risk if no studies have suggested such a risk. Jesse Mitchell, the plaintiff in the case, disagrees. Mitchell used AndroGel for several years, until suffering a heart attack in 2012. Mitchell and his doctors believe that AndroGel was the cause of the heart attack. He filed suit in 2013.
AndroGel drew the attention of the U.S. Food and Drug Administration (FDA) in 2014, when several studies suggested that the potential connection between AndroGel topical testosterone therapy medication and heart attacks merited further investigation.
Legal and medical experts are watching closely the AndroGel trial, which has the potential to establish a precedent in cases involving this controversial drug.
If your health has been jeopardized by Big Pharma’s quest for profits, contact TheLawFirm.com to learn how we can help you.
Androgel side effects lawsuit
Androgel insufficient labelling lawsuit
Does Androgel do more harm than good?
Androgel misleading ads lawsuit
Androgel Illinois verdict
Doctor testifies about Androgel and heart attacks risks
Abbvie claims FDA never requested study of Androgel and risk of heart attacks
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!